NASDAQ:PHVS Pharvaris Q2 2026 Earnings Results & Report $30.02 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$30.03 +0.01 (+0.03%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Pharvaris missed analyst earnings expectations in its Q2 2026 results, released August 12, 2026. The company reported EPS of -$0.81 versus the -$0.7467 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 12, 2026TimeBefore Market OpensConference Call7:00 AM ET Pharvaris EPS ResultsActual EPS-$0.81Consensus EPS -$0.7467Beat/MissMissed by -$0.0633One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersPharvaris Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsPharvaris' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) Pharvaris Q2 2026 Earnings FAQ Did Pharvaris beat earnings estimates for Q2 2026? Pharvaris (NASDAQ:PHVS) reported earnings of -$0.81 per share for Q2 2026, missing the consensus estimate of -$0.7467. The report was announced on Wednesday, August 12, 2026. When is Pharvaris' next earnings date? Pharvaris' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Pharvaris on the company's earnings history page. Pharvaris Earnings HeadlinesPharvaris FY2028 Earnings Forecast Boosted by HC WainwrightOctober 10, 2026 | americanbankingnews.comPharvaris' Rare Disease Drug Meets Primary, Secondary Goals in Phase 3 TrialOctober 9, 2026 | finance.yahoo.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.October 14 at 1:00 AM | Profits Run (Ad)Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The LancetOctober 9, 2026 | markets.businessinsider.comPharvaris' Deucrictibant XR Cuts HAE Attack Rate By 83%; Plans NDA Filing In H1 2027October 9, 2026 | rttnews.comPhase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The LancetOctober 8, 2026 | globenewswire.comSee More Pharvaris Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pharvaris? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharvaris and other key companies, straight to your email. Email Address About PharvarisPharvaris (NASDAQ:PHVS) (NASDAQ:PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE) and other diseases associated with bradykinin-mediated swelling. HAE is a rare genetic disorder that can cause recurring, potentially life-threatening attacks affecting areas such as the skin, gastrointestinal tract and airways. The company’s lead program is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist formerly known as PHA121. Pharvaris is evaluating deucrictibant in immediate-release and extended-release formulations for the on-demand treatment and prevention of HAE attacks. The company’s development strategy is intended to provide convenient oral alternatives to injectable or infused therapies. Pharvaris was founded by individuals with experience in HAE drug development and has operations in Europe and the United States. The company is advancing its pipeline through international clinical development programs and became a publicly traded company in 2021. Its headquarters are in Zug, Switzerland.View Pharvaris ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
